Recurrence-associated mortality in patients with differentiated thyroid carcinoma

✍ Scribed by Dr. Yodphat Krausz; Beatrice Uziely; Haim Karger; Ruth Isacson; Raphael Catane; Benjamin Glaser

• Publisher: John Wiley and Sons
• Year: 1993
• Tongue: English
• Weight: 493 KB
• Volume: 52
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930520309

✦ Synopsis

Abstract

Differentiated thyroid carcinoma (DTC) is associated with prolonged natural history, and even recurrent tumor is not necessarily followed by increased mortality. Prognostic factors and different treatment strategies, therefore, are difficult to assess. One hundred and fifty‐seven patients were followed in our clinic. In an attempt to predict mortality from this tumor, we evaluated the risk factors in 36 patients who presented with recurrent disease. Ten of these patients died. Age above 40 years at initial diagnosis was the predominant risk factor associated with 44% mortality after recurrence. Male sex, lack of radioiodine treatment, and distant site of initial recurrence were all associated with a trend towards increased mortality. Tumor histology and local invasion or extent of initial surgical treatment failed to affect mortality. In conclusion, this approach may be used to identify those patients who will die from their disease, despite currently available treatment. It remains to be seen, however, if new treatment protocols can be developed to improve the prognosis of these patients. © 1993 Wiley‐Liss, Inc.